Висока важливість
27 жовт. 2026 р.
This study is significant as it looks into a possible new treatment option for individuals experiencing severe nosebleeds due to HHT. While the findings indicate potential benefits, it is vital for patients to continue discussions with healthcare providers about treatment possibilities.
To investigate whether taking Pazopanib daily for 24 weeks can lessen the severity of nosebleeds in patients with hereditary hemorrhagic telangiectasia (HHT).
The findings suggest that Pazopanib may help reduce the seriousness of nosebleeds, although specific details and statistics are not provided. Detailed safety and effectiveness results are necessary for a clearer understanding.
Patients took part in a trial where they received either the active drug (Pazopanib) or a placebo (an inactive sugar pill). The trial assessed the severity and duration of nosebleeds, the amount of blood loss, and safety throughout the study.
The absence of detailed data on effectiveness makes it challenging to draw firm conclusions. The specifics of the trial indicate that further analysis is needed for accurate results.
Статус:
Фаза: Phase 2, Phase 3
Хто може брати участь: 18 Years – 85 Years · Будь-яка стать
Країни проведення: United States
Для вашого лікаря:
ClinicalTrials.gov: NCT03850964
Показано англійською
During the Efficacy Study (Part B), the investigators will study whether Pazopanib, taken daily for 24 weeks, will reduce the severity of nose bleeds in patients with hereditary hemorrhagic telangiectasia (HHT). Patients will either be provided active drug or a placebo \[sugar - inactive pill\], and be tested for nose bleed severity throughout the trial, including particularly nose bleed duration. Investigators will also test for blood loss, as well as for safety. This study is funded by the US Department of Defense USAMRAA and FDA/OOPD.